Physician profile
Craig Bobson
NPI 1790772986
$18,719.02
in general payments reported to CMS, 2019-2025
54 companies · $2,415 in 2025
The $2,415 reported for 2025 was more than what 95% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,482 · 2020: $2,168 · 2021: $3,686 · 2022: $2,689 · 2023: $1,941 · 2024: $2,338 · 2025: $2,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,677 · Education: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,676.57 |
| Education | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,019.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,691.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,497.58 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,325.13 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Lilly USA, LLC | $1,107.23 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,061.70 | 2019-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $728.46 | 2019-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $612.78 | 2019-2025 | |
| Esperion Therapeutics, INC. | $545.45 | 2020-2025 | Nexletol |
| Lundbeck LLC | $534.85 | 2021-2025 | Rexulti |
| Amgen INC. | $530.38 | 2019-2025 | Repatha, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $498.10 | 2019-2023 | Xarelto |
| Mylan Specialty L.P. | $495.73 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $367.20 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $353.62 | 2019-2025 | Trintellix |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Bobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.